Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-028 Estimated average burden								
	hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hunder Naomi						2. Issuer Name and Ticker or Trading Symbol Silverback Therapeutics, Inc. [SBTX]									ck all applic Directo Officer	all applicable) Director Officer (give title		Person(s) to Issuer 10% Owner Other (specify	
(Last) C/O SIL' 500 FAII		3. Date of Earliest Transaction (Month/Day/Year) 05/02/2022									Chief Medical Officer								
(Street) SEATTL (City)	E W	/A	98109 (Zip)		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable te) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	ole I - Nor	n-Deriv	ativ	e Se	curities	s Acc	quired,	Dis	posed o	f, or Be	ene	ficially	/ Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		3. Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)				5. Amou Securitie Beneficia Owned F Reported	es ally following	Form (D) o	. Ownership orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) (D)	or	Price	Transact (Instr. 3	ion(s)			(111341. 4)
Common Stock 05/02/					/2022		Α		43,177	177 ⁽¹⁾ A \$		\$0.00	54,427			D			
		-	Table II -								osed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Date,	I. Fransa Code (I		of		6. Date Exercisable Expiration Date (Month/Day/Year))	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		curity	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)		Date Exercisab		Expiration Date	Title	or Nu of	umber					
Stock Option (right to buy)	\$3.15	05/02/2022			A		86,355		(2)		05/01/2032	Common Stock	86	6,355	\$0.00	86,35	5	D	

Explanation of Responses:

- 1. The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
- 2. The shares subject to the option will vest on May 2, 2023.

Remarks:

/s/ Jeffrey C. Pepe, Attorney-in-

Fact

** Signature of Reporting Person Date

05/04/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.